Key facts
- Gallant’s last known valuation is $72.0M (Jun 2025).
- It has raised $60.5M; the latest was Later Stage VC ($18.0M) in Jun 2025.
- Notable investors include Alumni Ventures, Unpopular Ventures, Slow Ventures, Bling Capital, Digitalis Ventures — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Gallant
- ·The full record, as it builds
Funding rounds
No funding rounds for Gallant are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gallant
Developer of a pet health technology platform designed to deliver regenerative stem cell therapies for improved veterinary care. The company's platform offers standardized stem cell banking, allogeneic treatments, and controlled field trials of off-the-shelf stem cell therapies grounded in scalable science, enabling veterinarians in primary care settings to provide improved treatment options and better health outcomes for companion animals.
- Sector
- Business Products and Services (B2B)
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Employees
- 50
- Website
- gallant.com/
- Ownership
- Privately Held (backing)
Gallant doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gallant shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gallant in its N-PORT filings yet. We sweep new filings monthly.